Summary

Executive Summary

Azoth Analytics has released a research report titled “Global IL-17 Biologics Market (2023 Edition)” which provides a complete analysis of the Global IL-17 Biologics industry in terms of market segmentation By Indication (Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis), By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region and By Country. The data has been presented for the year 2022, the estimates for 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC) and 9 countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, Australia). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global IL-17 Biologics Market is expected to generate USD 10.9 Billion by the end of 2030, up from USD 4.37 Billion in 2022. A favourable growth element for the global IL-17 Biologics market is the increasing prevalence of autoimmune and inflammatory diseases, the effectiveness of these drugs in managing these conditions, and the demand for innovative treatments. During the forecast period, 2024-2030, Global IL-17 Biologics is expected to expand at a CAGR of 12.3 %. The implementation of patient support programs, including financial assistance, educational resources, and access to healthcare professionals, enhanced patient adherence and overall satisfaction with IL-17 biologics. These programs are pivotal in ensuring the success of these treatments.

According to the National Stem Cell Foundation, nearly 4% of the world’s population is affected by one of more than 80 different autoimmune diseases. Autoimmune diseases represent the third most common cause of chronic illness in the United States. For unknown reasons, the prevalence of autoimmune diseases is increasing. The use of IL-17 inhibitors in these autoimmune disorders reflects the versatility and potential of this class of biologics in managing various conditions characterized by immune system dysregulation and inflammation.

Advancements in monoclonal antibody engineering have led to the development of highly targeted IL-17 biologics. Techniques like antibody humanization and affinity maturation help create more effective and specific biologics with reduced side effects.

To ensure the long-term safety and efficacy of IL-17 biologics, innovative immunogenicity testing methods have been developed to monitor and manage immune responses to these treatments. These tests play a crucial role in detecting the development of anti-drug antibodies, thereby maintaining treatment effectiveness. Technological advancements have led to the development of innovative drug delivery systems for IL-17 biologics. For instance, autoinjectors have been created to make self-administration easier for patients. Cosentyx (Secukinumab) is available in a pre-filled syringe or autoinjector, enhancing patient convenience.

The IL-17 biologics market is expanding as these drugs receive regulatory approvals for additional autoimmune disease indications. For instance, Secukinumab was initially approved for treating psoriasis and later received approval for ankylosing spondylitis and psoriatic arthritis, broadening its market potential. The growth in indications increases the patient population eligible for IL-17 biologics.

Scope of the Report

• The report analyses the IL-17 Biologics Market by Value (USD Million).

• The report presents the analysis of the IL-17 Biologics Market for the year 2022, estimates of 2023 and the forecast period of 2024-2030.

• The report analyses the IL-17 Biologics Market by Indication (Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis).

• The report analyses the IL-17 Biologics Market by Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Eli Lilly and Company, UCB and AstraZeneca PLC.

ページTOPに戻る

Table of Contents

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology



2. Strategic Recommendations

3. Global IL-17 Biologics Market Assessment

3.1 Impact Analysis of Macro Economic Factors on Global IL-17 Biologics Market

3.2 Epidemiology

3.3 Pipeline Development of IL-17 Biologics

3.4 Global IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

3.5 Degree of Impact of Covid-19 on IL-17 Biologics Market

3.6 Global IL-17 Biologics Market Segmentation: By Indication

3.6.1 Global IL-17 Biologics Market, By Indication Overview

3.6.2 Global IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)

3.6.3 Global IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)

3.6.4 Global IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)

3.7 Global IL-17 Biologics Market Segmentation: By Drug

3.7.1 Global IL-17 Biologics Market, By Drug Overview

3.7.2 Global IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)

3.7.3 Global IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)

3.7.4 Global IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)

3.7.5 Global IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)



4. Global IL-17 Biologics Market, Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot



5. Americas IL-17 Biologics Market Assessment (2022-2030)

5.1 Americas IL-17 Biologics Market: Snapshot

5.2 Americas IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

5.3 Americas IL-17 Biologics Market: Key Factors

5.4 Americas IL-17 Biologics Market: Segment Analysis

5.5 Americas IL-17 Biologics Market Segmentation: By Indication

5.5.1 Americas IL-17 Biologics Market, By Indication Overview

5.5.2 Americas IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)

5.5.3 Americas IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)

5.5.4 Americas IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)

5.6 Americas IL-17 Biologics Market Segmentation: By Drug

5.6.1 Americas IL-17 Biologics Market, By Drug Overview

5.6.2 Americas IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)

5.6.3 Americas IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)

5.6.4 Americas IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)

5.6.5 Americas IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)

5.7 Americas IL-17 Biologics Market Segmentation: By Country

5.7.1 Americas IL-17 Biologics Market, By Country Overview

5.7.2 United States IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

5.7.2.1 United States IL-17 Biologics Market, By Indication

5.7.2.2 United States IL-17 Biologics Market, By Drug

5.7.3 Canada IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

5.7.3.1 Canada IL-17 Biologics Market, By Indication

5.7.3.2 Canada IL-17 Biologics Market, By Drug

5.7.4 Rest of Americas IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

5.7.4.1 Rest of Americas IL-17 Biologics Market, By Indication

5.7.4.2 Rest of Americas IL-17 Biologics Market, By Drug



6. Europe IL-17 Biologics Market Assessment (2022-2030)

6.1 Europe IL-17 Biologics Market: Snapshot

6.2 Europe IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

6.3 Europe IL-17 Biologics Market: Key Factors

6.4 Europe IL-17 Biologics Market: Segment Analysis

6.5 Europe IL-17 Biologics Market Segmentation: By Indication

6.5.1 Europe IL-17 Biologics Market, By Indication Overview

6.5.2 Europe IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)

6.5.3 Europe IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)

6.5.4 Europe IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)

6.6 Europe IL-17 Biologics Market Segmentation: By Drug

6.6.1 Europe IL-17 Biologics Market, By Drug Overview

6.6.2 Europe IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)

6.6.3 Europe IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)

6.6.4 Europe IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)

6.6.5 Europe IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)

6.7 Europe IL-17 Biologics Market Segmentation: By Country

6.7.1 Europe IL-17 Biologics Market, By Country Overview

6.7.2 Germany IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

6.7.2.1 Germany IL-17 Biologics Market, By Indication

6.7.2.2 Germany IL-17 Biologics Market, By Drug

6.7.3 United Kingdom IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

6.7.3.1 United Kingdom IL-17 Biologics Market, By Indication

6.7.3.2 United Kingdom IL-17 Biologics Market, By Drug

6.7.4 France IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

6.7.4.1 France IL-17 Biologics Market, By Indication

6.7.4.2 France IL-17 Biologics Market, By Drug

6.7.5 Spain IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

6.7.5.1 Spain IL-17 Biologics Market, By Indication

6.7.5.2 Spain IL-17 Biologics Market, By Drug

6.7.6 Rest of Europe IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

6.7.6.1 Rest of Europe IL-17 Biologics Market, By Indication

6.7.6.2 Rest of Europe IL-17 Biologics Market, By Drug



7. Asia Pacific IL-17 Biologics Market Assessment (2022-2030)

7.1 Asia Pacific IL-17 Biologics Market: Snapshot

7.2 Asia Pacific IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

7.3 Asia Pacific IL-17 Biologics Market: Key Factors

7.4 Asia Pacific IL-17 Biologics Market: Segment Analysis

7.5 Asia Pacific IL-17 Biologics Market Segmentation: By Indication

7.5.1 Asia Pacific IL-17 Biologics Market, By Indication Overview

7.5.2 Asia Pacific IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)

7.5.3 Asia Pacific IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)

7.5.4 Asia Pacific IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)

7.6 Asia Pacific IL-17 Biologics Market Segmentation: By Drug

7.6.1 Asia Pacific IL-17 Biologics Market, By Drug Overview

7.6.2 Asia Pacific IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)

7.6.3 Asia Pacific IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)

7.6.4 Asia Pacific IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)

7.6.5 Asia Pacific IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)

7.7 Asia Pacific IL-17 Biologics Market Segmentation: By Country

7.7.1 Asia Pacific IL-17 Biologics Market, By Country Overview

7.7.2 China IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

7.7.2.1 China IL-17 Biologics Market, By Indication

7.7.2.2 China IL-17 Biologics Market, By Drug

7.7.3 Japan IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

7.7.3.1 Japan IL-17 Biologics Market, By Indication

7.7.3.2 Japan IL-17 Biologics Market, By Drug

7.7.4 Australia IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

7.7.4.1 Australia IL-17 Biologics Market, By Indication

7.7.4.2 Australia IL-17 Biologics Market, By Drug

7.7.5 Rest of Asia Pacific IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)

7.7.5.1 Rest of Asia Pacific IL-17 Biologics Market, By Indication

7.7.5.2 Rest of Asia Pacific IL-17 Biologics Market, By Drug



8. Market Dynamics

8.1 Impact Assessment of Market Dynamics on Global IL-17 Biologics Market

8.2 Drivers

8.3 Restraints

8.4 Trends



9. Industry Ecosystem Analysis

9.1 Porter Analysis



10. Competitive Positioning

10.1 Companies’ Product Positioning

10.2 Market Share of Leading Companies

10.3 Company Profiling

10.3.1 Novartis

10.3.2 Eli Lilly and Company

10.3.3 UCB

10.3.4 AstraZeneca PLC